WIC
ABUS icon

Woodmont Investment Counsel’s Arbutus Biopharma ABUS Stock Holding History

Woodmont Investment Counsel’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-800
Closed -$3K – 187
2016
Q3 		$3K Buy
+800
New +$3.13K ﹤0.01% 594
2016
Q2 		– Sell
-800
Closed -$3K – 189
2016
Q1 		$3K Hold
800
– – ﹤0.01% 477
2015
Q4 		$4K Hold
800
– – ﹤0.01% 475
2015
Q3 		$5K Buy
+800
New +$7.09K ﹤0.01% 461

Other funds holding ABUS

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return

Woodmont Investment Counsel's ABUS Position: Q4 2016 in Review

Woodmont Investment Counsel sold out of Arbutus Biopharma (ABUS) in Q4 2016, closing a stake of 800 shares — an estimated $3K sold.

Woodmont Investment Counsel first reported a position in ABUS in Q3 2015 and held it in 4 quarters. The position peaked at $5K in Q3 2015. 55 funds tracked by Wall St. Rank hold ABUS as of Q4 2016.

  • Woodmont Investment Counsel reported no remaining Arbutus Biopharma position as of Q4 2016 after selling out during the quarter.
  • Woodmont Investment Counsel sold 800 Arbutus Biopharma shares in Q4 2016, an estimated $3K.
  • Woodmont Investment Counsel first reported a position in Arbutus Biopharma in Q3 2015 and held it in 4 quarters.
  • Woodmont Investment Counsel's Arbutus Biopharma position peaked at $5K in Q3 2015.
  • 55 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2016.

Based on Woodmont Investment Counsel's 13F filing for Q4 2016, filed 13 Feb 2017.